Amgen’s MD&A describes its use of data-driven information management to support operational decisions, noting that “we monitor the inventory levels of our products at our wholesalers by using data from our wholesalers and other third parties, and we believe wholesaler inventories have been maintained at appropriate levels,” which reflects the firm’s capability to provide timely and reliable information for internal processes. The discussion of global access to “cash, cash equivalents and marketable securities” and an investment policy that “limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings” and “places restrictions on maturities and concentration by asset class and issuer” illustrates the coordination and deployment of financial resources in support of strategic objectives. Further, Amgen details its financial risk management practices, including the use of “interest rate swap contracts that effectively converted a fixed-rate interest coupon for certain of our debt issuances to a floating LIBOR-based coupon” and “cross-currency swap contracts, which effectively convert the interest payments and principal repayment of the respective notes from euros, pounds sterling and Swiss francs to U.S. dollars,” underscoring the integration of external market data and internal governance processes to manage currency and interest-rate exposures. The company also emphasizes that its “investment policy” and “capital allocation” framework enable it to deploy cash flows for “payment of dividends, stock repurchases, repayment of debt and strategic transactions that expand our portfolio of products in areas of therapeutic interest,” and that the “timing and amount of future dividends and stock repurchases will vary based on a number of factors, including … availability of financing on acceptable terms,” demonstrating the mobilization and reconfiguration of resources in response to changing business needs.